CompletedNot Applicable

FIBRotic Interstitial Lung Disease and Nocturnal OXygen

United Kingdom102 participantsStarted 2018-12-17

Plain-language summary

Home sleep studies - which allow the measurement of breathing while the person sleeps - will be performed on patients with fibrotic interstitial lung disease attending two of the UK's largest respiratory medicine services.The study will investigate at how symptoms, and breathing and exercise tests differ between these two groups after 12 months of study.

Who can participate

Age range20 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * MDT diagnosis of fibrotic interstitial lung disease including but not limited to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), chronic hypersensitivity pneumonitis (CHP), fibrotic organising pneumonia and unclassifiable fibrotic lung disease. * Competent to provide written consent in English Exclusion Criteria: * Presence of an underlying connective tissue disease * Daytime/resting hypoxaemia with pO2 \<8.0 * Other indication for oxygen therapy * 3% ODI \>15 events/hour studied or established on CPAP * Predominant emphysema on CT * Inability to provide informed consent or complete health-related quality of life questionnaires in English * Current participation in a research project which might alter lung function or sleep study results

What they're measuring

Quality of life measured by King's Brief Interstitial Lung Disease Questionnaire (K-BILD)

Timeframe: 0 months,12 months

Trial details

NCT IDNCT04586946

SponsorGuy's and St Thomas' NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-30

View on ClinicalTrials.gov More Idiopathic Pulmonary Fibrosis trials